A significant number of patients with clinically diagnosed FH do not have mutations in LDLR, APOB, or PCSK9. It has been estimated that approximately 40% of patients with “possible FH” (as defined by the DLCN criteria) carry a known pathogenic variant in one of these genes (25). Here, PCSK9 is linked to familial hyperaldosteronism.